Annual report [Section 13 and 15(d), not S-K Item 405]

Accounts Payable and Accrued Expenses (Tables)

v3.25.1
Accounts Payable and Accrued Expenses (Tables)
12 Months Ended
Dec. 31, 2024
Accounts Payable and Accrued Expenses  
Schedule of Accounts Payable and Accrued Expenses

​

​

​

​

​

​

​

​

​

December 31,

($ in thousands)

​

2024

    

2023

Accounts payable

​

$

7,464

​

$

6,322

Accrued research and development

​

​

330

​

​

4,118

Accrued compensation

​

​

93

​

​

2,838

Other (1)

​

​

1,599

​

​

739

Total accounts payable and accrued expenses

​

$

9,486

​

$

14,017

​

​

(1) Other includes approximately $1.3 million of accrued consideration for the uBriGene Asset Purchase Agreement, see Note 5.